limited cutaneous systemic sclerosis
limited cutaneous systemic sclerosis
Explore linked clinical trials. Standard reference: MONDO:00163582 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, limited cutaneous systemic sclerosis, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-09-02 | NCT02682511 | |
| A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, interstitial lung disease, limited cutaneous systemic sclerosis, lung disorder, respiratory system disorder, skin disorder, systemic sclerosis | Recruiting | Phase 2 | 2026-03-31 | NCT07047690 |